2024 NOSCM | Lung Cancer With EGFR Exon 19 and L858R Mutations: The Optimal Front Line Therapy
Overview
NA
Target Audience
NA
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Jonathan Riess, MD, MS
Date of Release
May 14th, 2025
-1750785214433.webp&w=3840&q=75)
-1750780084008.webp&w=3840&q=75)